Metabolic Disorder Sidelines Ex-Hertha Talent Eichhorn
Translated from German, summarized and contextualized by DistantNews.
At a glance
- Bayer Leverkusen's new 17-year-old signing, Kennet Eichhorn, will be sidelined due to a metabolic disorder.
- The condition followed a high physical strain and significant weight loss after a gastrointestinal illness.
- The club is committed to supporting Eichhorn's recovery, prioritizing his health over immediate playing time.
Bundesliga club Bayer Leverkusen announced that their promising 17-year-old recruit, Kennet Eichhorn, will be taking an indefinite break from football due to a diagnosed metabolic disorder. The condition was identified during a medical examination, and the club confirmed that it requires treatment. Eichhorn, formerly of Hertha BSC, had experienced significant physical strain and subsequent weight loss following a gastrointestinal illness, which is believed to have preceded the metabolic issue.
Simon Rolfes, Leverkusen's managing director of sport, emphasized the club's full support for the young talent. "Kennet is facing what we hope will be a very long career at the highest level. We will support him in this path as best we can," Rolfes stated. He added, "What is important at this stage is that we have initiated the right measures for his recovery and that Kennet receives the necessary time and peace for his treatment without pressure."
Eichhorn is expected to begin his treatment at a specialized facility. Bayer Leverkusen has not provided a timeline for his return to play. Speculation about a persistent infection had circulated in the days leading up to the team's training camp. Eichhorn, who was reportedly courted by top European clubs, transferred from Berlin to Leverkusen in the summer for an estimated nine million euros. Last season, he played 19 games for the Hertha BSC first team, despite being only 16 years old.
Originally published by Die Zeit in German. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.